F
Fractyl Health
Working to liberate patients, empower physicians and lower health care costs by developing device-based solutions to metabolic diseases
About Fractyl Health
Fractyl is a pioneering healthcare startup that is focused on developing innovative therapies for the treatment of Type 2 Diabetes (T2D) and obesity. The company's primary market is patients suffering from these metabolic diseases. The company's mission is to create transformative therapies that can prevent and eliminate these diseases by targeting their root causes.
Read full description
Fractyl's business model revolves around the development and commercialization of its breakthrough therapies. The company's main product in development is Rejuva, a novel gene therapy platform that is designed to improve the function of islet cells in the pancreas, which play a crucial role in regulating blood sugar levels. By enhancing the function of these cells, Fractyl aims to enable long-term remission of T2D and obesity.
Rejuva is currently in the preclinical development stage and is being tested under the oversight of the United States Food & Drug Administration (FDA). While it has not yet received full regulatory approval, it has shifted from investigational use to commercial availability with a CE mark, which indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area.
Fractyl generates revenue through the development, regulatory approval, and subsequent commercialization of its therapies. The company's financial success hinges on the successful development and approval of its products, as well as their acceptance and adoption by healthcare providers and patients.
At a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Lexington, United States
- Listing
- IPO 2024
- Employees
- 107
- Open positions
- 3
- Dealroom signal
- 69.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Weight Management, Metabolism, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Fractyl Health.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $60M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Aug 2025 | $20M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$55M | — |
| 2025 | $0 | -100% | −$55M | — |
| 2024 | $93K | -22.5% | −$111M | -119098.9% |
| 2023 | $120K | — | −$44M | -36463.3% |
| 2022 | $0 | — | −$49M | — |
| 2021 | $0 | — | −$36M | — |
| 2020 | $0 | — | −$28M | — |
Growth signals
Latest recorded traffic for Fractyl Health is 6.9K monthly website visits, down 46.9% over the last three months. Fractyl Health's team declined 1.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Mithril
Bessemer Venture Partners
Domain Associates
General Catalyst
Series B and later13 investors entered at this stage
Deerfield
GV
True Ventures
IDo Fund- EPEmergent Medical Partners
CDIB Capital Group
Catalio Capital Management
Taiwania Capital
Z Venture Capital
Maverick Capital
M28 Capital
Population Health Partners- CVCDIB Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fractyl Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fractyl Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.